Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02946047 · ClinicalTrials.gov registry record · Phase 1
The Effect of Ixazomib on the Latent HIV Reservoir
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02946047: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02946047 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02946047, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary purpose of the trial is to determine the safety and tolerability of ixazomib in HIV infected patients on antiretroviral therapy. The secondary purpose is to determine the effect of ixazomib on the size of the HIV reservoir.
Interventions
- DRUG Ixazomib 1 MG
- DRUG Ixazomib 2 MG
- DRUG Ixazomib 3 MG
- DRUG Ixazomib 4 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02946047
The ClinicalTrials.gov registry entry for NCT02946047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ixazomib 1 MG is the first listed.
NCT02946047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02946047 about?
NCT02946047 is a clinical study titled "The Effect of Ixazomib on the Latent HIV Reservoir". The primary purpose of the trial is to determine the safety and tolerability of ixazomib in HIV infected patients on antiretroviral therapy. The secondary purpose is to determine the effect of ixazomib on the size of the HIV reservoir.
What is the current status of trial NCT02946047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-03-20. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT02946047?
The interventions under investigation include: Ixazomib 1 MG (DRUG), Ixazomib 2 MG (DRUG), Ixazomib 3 MG (DRUG), Ixazomib 4 MG (DRUG).
Who is sponsoring clinical trial NCT02946047?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.